(HealthDay News) — For patients with type 2 diabetes, the DiaRem score can identify those who are likely to be cured by Roux-en-Y gastric bypass (RYGB) surgery, according to a research letter published in JAMA Surgery.
G. Craig Wood, from the Geisinger Health System in Danville, and colleagues conducted an electronic health record review up to 8 years after RYGB surgery for 407 patients with type 2 diabetes. The DiaRem score (a weighted score based on age, insulin dependence, diabetes medication use, and HbA1c level) and extent of diabetes remission after surgery were determined for each of the patients, with a median follow-up of 7.1 years.
The researchers found that 35% and 24% of the patients experienced 1 or more years of complete and partial remission, respectively. Diabetes cure occurred in 20%, and another 25% experienced prolonged partial remission.
As DiaRem scores increased, the proportion of patients achieving remission decreased, for remissions of any duration (P<.001). The proportion of patients achieving partial remission was 82% among patients with a DiaRem score of 0 to 2, compared with 0% among those with a score of 18 or higher; for diabetes cured, the corresponding proportions were 50% and 0%.
“The DiaRem score predicts who will be cured by surgery, defined as complete remission lasting at least 5 years,” the researchers wrote.
The study was funded by Geisinger Clinic.